Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $79K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $79K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $79K or moves back toward the trailing-twelve-month quarterly average of $19.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$79K— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$79K+2.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.6% is the 4th highest of 10, against a peer median of -18.4%.
CGEM Competitors
Cost of Revenue for CGEM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M USD+63.0%+84.1%43.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M USD-56.9%-53.2%13.5%
XNCRXencor, Inc.LTM Jun 2026$59.51M USD-6.4%-62.5%56.7%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$9.91M USD-79.7%+34.1%45.9%
CGENCompugen Ltd.LTM Mar 2026$8.68M USD+5.4%+111.7%11.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$7.35M USD+33.7%+32.5%9.3%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$150K USD-31.8%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$79K USD+2.6%——
IMTXImmatics N.V.LTM Mar 2026€0 EUR-100.0%—0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding CGEM) —-18.4%+34.1%21.8%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.